Baxter International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on October 24, 2019, by Baxter International Inc. The filing primarily addresses the commencement of an internal investigation into accounting misstatements and provides updates on regulatory and legal matters. The report references preliminary operating results for the quarter ended September 30, 2019, which were issued via a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it discloses historical misstatements in non-operating income related to net foreign exchange gains within "Other (income) expense, net" for the following periods:
- 2014: $8 million
- 2015: $113 million
- 2016: $28 million
- 2017: $50 million
- 2018: $73 million
- First half of 2019: $22 million
The filing notes that these figures were generated using a foreign exchange rate convention not in accordance with generally accepted accounting principles (GAAP).
Material Changes and Investigation Details
The Company announced an internal investigation into intra-Company transactions designed to generate foreign exchange gains or losses. These transactions utilized a non-GAAP convention that allowed transactions to be executed after exchange rates were known. The Audit Committee is overseeing the investigation with external counsel and consultants. The Company has voluntarily notified the SEC and does not expect to file its Form 10-Q for the period ended September 30, 2019, on a timely basis. The investigation is in its early stages, and the duration and outcome are unpredictable.
Outlook, Risks, and Contingencies
FDA Warning Letter: The U.S. FDA issued a Warning Letter regarding Claris Injectables Limited's facilities in Ahmedabad, India, following an inspection in 2017. While the letter remains in effect, Baxter has secured alternative manufacturing locations for a majority of planned new products for U.S. distribution. The Pharmaceuticals business unit remains committed to a $550 million new product revenue goal by 2023.
Litigation: In August 2019, Baxter was served with an amended complaint in the MDL In re: National Prescription Opiate Litigation by Fayette County, Georgia. The complaint alleges improper marketing and diversion of opiate products. The allegations against Baxter are limited and do not distinguish between injectable and oral opiates. Baxter manufactured generic injectable opiates at a facility in Cherry Hill, NJ, which was divested in 2011.
Investor Verification Checklist
- Verify the scope and potential financial impact of the internal investigation into foreign exchange accounting misstatements.
- Monitor the timeline for the delayed filing of the Form 10-Q for the quarter ended September 30, 2019.
- Track the status of the FDA Warning Letter regarding Claris Injectables and the progress of alternative manufacturing arrangements.
- Review developments in the National Prescription Opiate Litigation, specifically regarding the divested Cherry Hill facility.
- Confirm if the historical foreign exchange gain misstatements will require restatements of prior period financial statements.